The Curbsiders podcast

#527 Oncology Potpourri for the Hospitalist

June 1, 2026 | By

Audio

Video


Transcript available via YouTube

Malignant Bowel Obstruction, VTE and Goals of Care

Master malignant bowel obstruction, cancer-associated thrombosis, and goals-of-care conversations in hospitalized patients with advanced cancer. Learn practical approaches to symptom management, anticoagulation decisions, and navigating high-stakes discussions around prognosis and hospice care. We’re joined by  Dr. Jensa Morris, @JensaMorrisMD (Yale School of Medicine).

Claim free CME for this episode at curbsiders.vcuhealth.org!

Show Segments

  • Intro
  • Picks of the Week
  • Case 1: Malignant small bowel obstruction: definitions, initial management, medications, NG tubes, nutrition, and procedural options
  • Case 2: Cancer-associated VTE: choice of anticoagulant, treatment duration, unusual thromboses, and anticoagulation with brain metastases 
  • Case 3: Goals of care: prognosis, performance status, palliative care, hospice and end-of-life planningTake Home Points
  • Outro 

Oncology Potpourri for the Hospitalist Pearls

  1. Malignant bowel obstruction is often a marker of advanced disease and poor prognosis, particularly in patients with multifocal obstruction, ascites, or peritoneal carcinomatosis.
  2. Initial management of malignant SBO should prioritize symptom relief with bowel rest, IV fluids, antiemetics, opioids, and possibly NG decompression while simultaneously clarifying goals of care.
  3. Surgery is rarely beneficial in patients with diffuse carcinomatosis, poor functional status, or recurrent malignant SBO; early palliative care involvement is essential in these scenarios.
  4. Dexamethasone and antisecretory agents (e.g., octreotide) can meaningfully improve nausea, vomiting, and abdominal symptoms in malignant bowel obstruction.
  5. Total parenteral nutrition is usually not beneficial in advanced malignant SBO and should only be considered in carefully selected patients with meaningful expected survival and potential for further cancer-directed therapy.
  6. Most patients with brain metastases can still receive therapeutic anticoagulation when clinically indicated, but hospitalists should use extra caution and involve interdisciplinary discussion for malignancies with particularly hemorrhagic brain metastases, including melanoma, renal cell carcinoma, choriocarcinoma, and thyroid cancer.
  7. Patients with active malignancy and VTE generally require extended-duration anticoagulation as long as the cancer remains active or treatment is ongoing, though some patients may later transition to reduced-dose DOAC therapy during the extended treatment phase depending on bleeding risk and overall clinical context.
  8. Hospitalists should not wait for a “transition to comfort care” before involving palliative care—early consultation improves symptom management, communication, and discharge planning.

Oncology Potpourri for the Hospitalist

Malignant Bowel Obstruction

Defining Malignant Bowel Obstruction

Malignant bowel obstruction (MBO) refers to a partial or complete obstruction of the bowel distal to the ligament of Treitz caused directly or indirectly by malignancy (Anthony, et al., 2007). 

Compared with adhesive small bowel obstruction, which often presents more acutely in otherwise stable patients, malignant bowel obstruction is frequently a more subacute or progressive process associated with multifocal obstruction, ascites, cachexia, and ongoing cancer-related decline. 

CT abdomen/pelvis with IV contrast is typically the preferred imaging modality because it helps confirm the obstruction, identify complications, and assess overall disease burden.

Dr. Morris emphasizes that MBO is often a marker of advanced disease and poor prognosis, particularly in patients with recurrent obstruction, multifocal disease, ascites, or declining performance status. 

Initial Stabilization and Symptom Management 

Initial management generally centers on IV fluids, antiemetics, bowel decompression when needed, and adequate opioid therapy for symptom relief.

Dr. Morris emphasizes that even during the initial stabilization of malignant bowel obstruction, clinicians should begin exploring the patient’s understanding of their illness and overall trajectory. Establishing this context early helps guide decisions about decompression, procedures, symptom management, and overall treatment intensity throughout the hospitalization.

NG Tubes, Antiemetics, Opioids, and Antisecretory Therapy

For symptom management, Dr. Morris emphasizes that antiemetic selection in malignant bowel obstruction differs somewhat from standard nausea management and shares that she frequently uses the National Comprehensive Cancer Network guidelines to help guide management decisions in these patients (NCCN Clinical Practice Guidelines in Oncology: Palliative Care Version 2.2026). In patients with partial obstruction, metoclopramide can be helpful because of its pro-motility effects, though she cautions that she uses it carefully since a partial obstruction may later progress to a complete obstruction. In patients with complete obstruction, she avoids pro-motility agents.

Dr. Morris notes that antisecretory therapy is often a cornerstone of pharmacological management in MBO. Her preferred agent is octreotide, which can reduce gastrointestinal secretions and vomiting and is typically administered subcutaneously or IV multiple times daily. Additional commonly used antiemetics include olanzapine and haloperidol.

Dr. Morris also notes that corticosteroids are sometimes used as adjunctive therapy in malignant bowel obstruction (Walter et al., 2024 and Feuer et al., 1999), despite limited high-quality evidence. Her practice is to trial dexamethasone (commonly 2–4 mg IV) for several days in select patients, which is also consistent with the NCCN guidelines.

If patients remain significantly symptomatic despite initial medical management—particularly those with severe nausea, vomiting, or abdominal distention—Dr. Morris may recommend temporary nasogastric tube decompression. She notes that some patients experience dramatic relief after removal of several liters of gastric contents, though her preference is generally to avoid leaving NG tubes in place long term whenever possible.

Procedural Management: Surgery, Stenting, and Venting G Tubes

While some patients may benefit from surgery or endoscopic stenting, many patients with advanced malignancy, multifocal obstruction, or extensive peritoneal carcinomatosis are poor procedural candidates and are managed primarily with symptom-directed therapy. In addition to survival, she highlights the importance of discussing the burden of recurrent admissions and time spent in the hospital versus at home, since many patients with recurrent malignant SBO spend a substantial portion of their remaining life hospitalized (Olson et al., 2014).

For patients with recurrent or refractory symptoms, venting gastrostomy tubes can provide substantial symptomatic relief and reduce recurrent hospitalizations. Patients may be able to clamp the tube and resume some oral intake when feeling well, then unclamp it during episodes of worsening nausea, vomiting, or distention. She emphasizes that this approach can help patients avoid repeated emergency department visits and prolonged hospital stays while improving overall quality of life (Zucchi et al., 2016). 

Large-volume ascites can complicate venting G-tube placement because the stomach may not adequately appose the abdominal wall. In these situations, patients may require concurrent management of ascites—sometimes with placement of a tunneled peritoneal drain (e.g., Denver drain) at the same time as venting G-tube placement to facilitate the procedure and improve ongoing symptom control.

Nutrition, Hydration, and TPN in Malignant SBO

Dr. Morris notes that the NCCN palliative care guidelines generally discourage TPN when the underlying malignancy is expected to be the primary life-limiting process rather than starvation from the obstruction itself. However, she emphasizes that important exceptions exist. She describes select patients with more indolent malignancies who may have meaningful survival and quality-of-life benefit from long-term TPN in combination with supportive interventions like venting G tubes.

At the same time, Dr. Morris highlights that clinicians should recognize the overall literature does not demonstrate a consistent improvement in quality or quantity of life with TPN for most patients with advanced malignant bowel obstruction (Sowerbutts et al. 2018). These discussions should therefore remain individualized and grounded in prognosis, functional status, and the patient’s goals and priorities.

Cancer-Associated Venous Thromboembolism

Choosing Between DOACs and LMWH in Patients with Cancer

Dr. Morris explains that both direct oral anticoagulants (DOACs) and low molecular weight heparin (LMWH) are appropriate options for treatment of cancer-associated venous thromboembolism in many patients with solid tumors. The NCCN guidelines generally favor LMWH in patients with gastric or gastroesophageal malignancies because of the increased risk of hemorrhage in these cancers (NCCN Guidelines Version 1.2026 Cancer-Associated Venous Thromboembolic Disease).

Additionally, considering the patient’s concurrent cancer therapies when managing anticoagulation is important. She specifically notes that vascular endothelial growth factor (VEGF) inhibitors such as bevacizumab can paradoxically increase the risk of both thrombosis and bleeding. 

Duration of Anticoagulation in Active Malignancy 

The general principle of anticoagulation in cancer-associated thrombosis is that patients typically remain anticoagulated for as long as the malignancy is active or cancer-directed therapy continues. In practice, this often means indefinite anticoagulation for patients with metastatic disease.

She also highlights emerging data supporting dose reduction strategies during the extended treatment phase. Specifically, after six months of full-dose anticoagulation, some patients with ongoing active cancer may transition from apixaban 5 mg twice daily to 2.5 mg twice daily, based on newer trial data demonstrating similar efficacy with lower bleeding risk during long-term therapy (API-CAT Trial: Mahé, et al., 2025). Dr. Morris notes that the clinical relevance of this strategy depends heavily on the patient’s prognosis and overall trajectory.

Incidental PE, Visceral Vein Thrombosis, and Tumor Thrombus

Incidental pulmonary emboli are extremely common in patients with cancer, often identified on routine staging or surveillance imaging. Unlike in the general medical population—where isolated incidental subsegmental PE may sometimes be managed conservatively—she emphasizes that cancer-associated thrombosis is approached more aggressively. Per Dr. Morris, “every clot in cancer is an important clot,” and incidental PE in patients with active malignancy is generally treated with therapeutic anticoagulation similarly to symptomatic VTE.

The same general principle extends to incidental splanchnic and mesenteric vein thrombosis in patients with active malignancy. In most cases, these thrombi are treated similarly to DVT or PE with therapeutic anticoagulation because cancer-associated clots are considered clinically meaningful even when asymptomatic. 

Anticoagulation and Brain Metastases

Most patients with brain metastases can still receive therapeutic anticoagulation when clinically indicated, though certain malignancies warrant additional caution because of their higher risk of intracranial hemorrhage. Melanoma, renal cell carcinoma, thyroid cancer, and choriocarcinoma as malignancies with particularly increased risk of hemorrhagic brain metastases (Lin, et al., 2018) where multidisciplinary discussion is especially important before initiating therapeutic anticoagulation.

She also notes that the status of the brain metastases matters. Untreated brain metastases are generally more concerning for bleeding than previously treated lesions. For example, she describes feeling much more comfortable anticoagulating patients with treated brain metastases—such as lung cancer metastases managed with stereotactic radiosurgery—whereas newly discovered untreated metastases often prompt more careful interdisciplinary discussion. 

Prognosis and Performance Status in Advanced Cancer

Palliative Care Consultation and Goals-of-Care Conversations

Dr. Morris strongly advocates for early palliative care involvement, emphasizing that consultation should occur “early and often” rather than waiting until the final stages of illness or transition to hospice. In patients with recurrent malignant bowel obstruction, progressive disease, repeated hospitalizations, and worsening functional decline, palliative care can provide substantial support with symptom management, prognostic discussions, communication, and discharge planning. She highlights that these conversations are ideally introduced well before a patient reaches the final days or weeks of life.

One of the major strengths of palliative care is expert symptom management. While hospitalists may be comfortable with first-line approaches to pain, nausea, and vomiting, palliative care often provides additional expertise for refractory symptoms and more advanced therapies such as ketamine infusions, PCA management, and complex multidrug antiemetic regimens.

Palliative care is also a collaborative partner in communication and goals-of-care discussions. Although hospitalists on her service routinely lead serious illness conversations, she notes that these discussions are often most effective when conducted alongside palliative care clinicians who can provide additional support for patients, families, and the primary team.

Dr. Morris acknowledges that some patients with advanced cancer and poor prognosis may still choose life-prolonging treatment despite extensive discussions about prognosis and hospice. She emphasizes that goals-of-care conversations should remain centered on the patient’s wishes rather than the clinician’s preferences, and that clinicians must respect these decisions unless clear ethical concerns exist. 

Symptom Focused Management at End-of-Life

Dr. Morris acknowledges that transitions toward symptom-focused care and hospice can feel abrupt for patients and families, particularly when they were recently discussing additional cancer-directed treatment. She emphasizes the importance of explicitly recognizing this change in trajectory during conversations with patients.

She recommends using clear, empathetic language that connects the patient’s clinical decline to the underlying cancer progression. She sometimes shares that “patients in similar situations often make decisions like…” to help reduce the sense that the patient is facing an isolated or uniquely frightening choice. In her expert opinion, this framing can make discussions about hospice and comfort-focused care feel less overwhelming and more grounded in shared human experience.

Dr. Morris reflects on several communication pitfalls she has learned over time. One major mistake she cautions against is leading serious illness conversations by immediately discussing code status, which can prematurely narrow the discussion to resuscitation decisions before understanding the patient’s broader goals and priorities. Similarly, she tries to avoid framing conversations solely around a single intervention—such as surgery, TPN, or another escalation of care—because patients and families may understandably fixate on that individual decision rather than the overall clinical trajectory and bigger picture of what medical care is trying to accomplish.

Hospice and Discharge Planning

Dr. Morris emphasizes that successful hospice discharge planning requires careful coordination before the patient leaves the hospital. Her first priority is ensuring the patient is formally enrolled in hospice and that hospice services will evaluate the patient within 24 hours of discharge to help avoid unwanted return visits to the emergency department.

She also stresses the importance of arranging all necessary durable medical equipment (DME) and home supplies in advance, including hospital beds and any equipment related to symptom management such as venting G-tube supplies. Family education is equally important so caregivers feel prepared to manage medications, drains, tubes, and expected symptom changes at home.


Links

Nashville Themed Picks of the Week:

  1. Chapstick
  2. Assembly Food Hall

Goal

Listeners will develop a practical approach to the hospitalized patient with malignant bowel obstruction and cancer-associated venous thromboembolism while incorporating prognosis and goals-of-care discussions.

Learning objectives

After listening to this episode listeners will…  

  1. Recognize and initiate management for malignant bowel obstruction in hospitalized patients.
  2. Identify patients who may benefit from procedural vs medical management of malignant bowel obstruction.
  3. Select appropriate anticoagulation for cancer-associated VTE, accounting for malignancy type and bleeding risk.
  4. Recognize when goals-of-care conversations and palliative care consultation should be prioritized in patients with advanced malignancy.

Disclosures

Dr. Morris reports no relevant financial disclosures. The Curbsiders report no relevant financial disclosures. 

Citation

Blackburn, R., Morris, J., Trubitt M, Amin M, Coleman C, Williams PN, Watto MF. “527 Oncology Potpourri for the Hospitalast”. The Curbsiders Internal Medicine Podcast. thecurbsiders.com/category/curbsiders-podcast Final publishing date June 1, 2026.

Episode Sponsors

Continuing Education Company

Visit CMEmeeting.org/curbsiders and use promo code Curb30 for 30% off all online courses and webcasts.

Locumstory

Locumstory.com is literally just a free, unbiased resource dedicated to educating physicians about locums.

Mint Mobile

To get your new wireless plan for just 15 bucks a month, go to mintmobile.com/CURB.

Episode Credits

Writer, producer, and show notes: Reaford Blackburn, Jr., MD
Infographic, Cover Art: Caroline Coleman, MD
Hosts: Monee Amin, MD and Meredith Trubitt, MD
Reviewer: Rahul Ganatra, MD
Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP
Technical Production: PodPaste
Guest: Jensa Morris, MD

CME Partner

vcuhealth

The Curbsiders are partnering with VCU Health Continuing Education to offer continuing education credits for physicians and other healthcare professionals. Visit ce.vcuhealth.org/curbsiders and search for this episode to claim credit.

Contact Us

Got feedback? Suggest a Curbsiders topic. Recommend a guest. Tell us what you think.

Contact Us

We love hearing from you.

Notice

We and selected third parties use cookies or similar technologies for technical purposes and, with your consent, for other purposes as specified in the cookie policy. Denying consent may make related features unavailable.

Close this notice to consent.